Vertex Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that Dr. Reshma Kewalramani, the company’s Chief Executive Officer and President, will present at the highly anticipated 44th Annual J.P. Morgan Healthcare Conference. The event is scheduled for Monday, January 12, 2026, at 5:15 p.m. ET (2:15 p.m. PT).

This annual conference is one of the most significant events in the healthcare sector, attracting a wide array of investors, analysts, and industry leaders. Vertex’s participation underscores its commitment to transparency and engagement with the investment community.

For those unable to attend in person, Vertex will provide a live webcast of Dr. Kewalramani’s remarks, which will be accessible through the company’s official website. Interested parties can find the webcast in the "Investors" section under the "News and Events" page. Furthermore, a replay of the conference presentation will be archived on the site for future viewing, ensuring that stakeholders can stay informed about the company's developments.

Vertex Pharmaceuticals is a global leader in biotechnology, dedicated to developing transformative medicines for serious diseases and conditions. The company has an impressive portfolio of approved therapies, particularly in treating cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. Additionally, Vertex is actively engaged in research and clinical programs aimed at addressing acute pain.

The company’s robust pipeline includes investigational therapies targeting a range of serious diseases. Vertex’s deep insight into causal human biology positions it well to tackle conditions such as neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1.

Founded in 1989 and headquartered in Boston, Vertex Pharmaceuticals has established itself as a beacon of innovation within the biopharmaceutical industry. The company also boasts an international headquarters in London, alongside research and development sites and commercial offices across North America, Europe, Australia, Latin America, and the Middle East.

Vertex's commitment to its workforce is evident, as it has been recognized as one of the industry's best places to work, earning a spot on Science magazine's Top Employers list for 16 consecutive years and ranking among Fortune’s 100 Best Companies to Work For.

As Vertex Pharmaceuticals gears up for its presentation at the J.P. Morgan Healthcare Conference, the biotech community will be keenly observing the insights shared by Dr. Kewalramani. With a strong commitment to scientific innovation and a diverse pipeline of therapies, Vertex continues to position itself as a leader in the biopharmaceutical landscape. For further updates and to learn more about Vertex’s pioneering efforts, stakeholders are encouraged to visit the company’s website or follow them on various social media platforms.